Incidence of asymptomatic urinary tract infections in patients with sodium Glucose Co- transporter (sglt2) inhibitors

Registration ID: IJNRD_205796

Published ID: IJNRD2309297

DOI: Click Here to Get

Nishath , Arshiya jahan , Dr.A.V.Kishore babu , Dr.A.Srinivas rao

Urinary tract infections (UTI), Sodium glucose co-transporter (SGLT-2) inhibitors, Placebo, Genital infections, Type -2 diabetes mellitus, Chronic kidney disease, Bacteriuria, Hypoglycaemia, Heart failure, Meta analysis.

Urinary tract infections (UTIs) are a common concern among patients with diabetes mellitus who are treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of hypoglycaemic medications. This systematic review and meta-analysis aimed to assess the incidence of UTIs in patients receiving SGLT2 inhibitors compared to other antidiabetic treatments or a placebo. A comprehensive literature search was conducted in major scientific databases, including PubMed, Embase, and Cochrane Library. Studies that reported the incidence of UTIs in adult patients with diabetes treated with SGLT2 inhibitors were included. The primary outcome measure was the incidence rate of UTIs, and secondary outcomes included the severity of UTIs and the association of UTIs with specific SGLT2 inhibitors. The pooled data revealed a higher overall incidence rate of UTIs in patients treated with SGLT2 inhibitors when compared to those on other antidiabetic therapies or placebo. Analysis based on specific SGLT2 inhibitors demonstrated varying degrees of UTI risk. Furthermore, the severity of UTIs in patients receiving SGLT2 inhibitors was found to be similar to those receiving alternative treatments or placebo. However, there was evidence of a higher frequency of genitourinary infections, particularly in females treated with SGLT2 inhibitors. The findings of this systematic review and meta-analysis highlight the increased risk of UTIs associated with SGLT2 inhibitor use in patients with diabetes. While SGLT2 inhibitors have shown significant benefits in glycaemic control, improving renal function and cardiovascular outcomes, physicians should be aware of this potential side effect and consider proper monitoring and preventive measures for patients at higher risk of developing UTIs. Future research may further explore the underlying mechanisms contributing to UTI risk with SGLT2 inhibitors and investigate strategies to alleviate this adverse effect.

Published Paper   E-Certificate

Nishath, Arshiya jahan, Dr.A.V.Kishore babu, & Dr.A.Srinivas rao (September-2023). Incidence of asymptomatic urinary tract infections in patients with sodium Glucose Co- transporter (sglt2) inhibitors . INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 8(9), c866-c869. https://ijnrd.org/papers/IJNRD2309297.pdf

Volume 8 Issue 9, September-2023

Pages : c866-c869

Paper Reg. ID: IJNRD_205796

Published Paper Id: IJNRD2309297

Downloads: 000121984

Research Area: Pharmacy

Country: RR district , Telangana , India

Published Paper PDF: https://ijnrd.org/papers/IJNRD2309297.pdf

Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2309297

Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)

ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG

This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition

Call For Paper - Volume 10 | Issue 10 | October 2025

IJNRD is a Scholarly Open Access, Peer-reviewed, and Refereed Journal with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost Journal that follows UGC CARE 2025 Peer-Reviewed Journal Policy norms, Scopus journal standards, and Transparent Peer Review practices to ensure quality and credibility. IJNRD provides indexing in all major databases & metadata repositories, a citation generator, and Digital Object Identifier (DOI) for every published article with full open-access visibility.

The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse fields. Its goal is to promote global scientific information exchange among researchers, developers, engineers, academicians, and practitioners. IJNRD serves as a platform where educators and professionals can share research evidence, models of best practice, and innovative ideas, contributing to academic growth and industry relevance.

Indexing Coverage includes Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many more recognized academic repositories.

How to submit the paper?

By Our website

Click Here to Submit Paper Online

By Mail

Send your paper to editor@ijnrd.org

Important Dates for Current issue

Paper Submission Open For: October 2025

Current Issue: Volume 10 | Issue 10 | October 2025

Impact Factor: 8.76

Last Date for Paper Submission: Till 31-Oct-2025

Notification of Review Result: Within 1-2 Days after Submitting paper.

Publication of Paper: Within 01-02 Days after Submititng documents.

Frequency: Monthly (12 issue Annually).

Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.

Subject Category: Research Area

Call for Paper: More Details